|
Daniela Berg - Eberhard Karls Universitaet Tuebingen
More InformationProf. Daniela Berg is working as a senior physician at the Centre of Neurology, Department of Neurodegeneration, University Hospital in Tübingen, Germany. She is leading the working group “Clinical Neurodegeneration” and is, amongst other roles, head of the outpatients’ clinic for Parkinsonian syndromes, responsible coordinator of clinical studies and head of the laboratory for transcranial sonography.
|
|
Nicola Pavese - University of Newcastle upon Tyne
More InformationAvailable soon
|
|
Jacques Demotes - European Clinical Research Infrastructure Network
More InformationJacques Demotes-Mainard (MD, PhD, MBA) is Neurologist and Professor of Cell Biology. Coordinator since 2004 of four FP6 and FP7 ECRIN projects, and currently Director-General of ECRIN-ERIC, a not-for-profit research infrastructure supporting multinational clinical trials in Europe.
|
|
David Devos - Centre Hospitalier Regional et Universitaire de Lille
More InformationAvailable soon.
|
|
Richard Dodel - Philipps Universitat Marburg
More InformationAvailable soon.
|
|
Dominique Deplanque - Centre Hospitalier Regional et Universitaire de Lille
More InformationAvailable soon.
|
|
Joaquim Ferreria - Instituto de Medicina Molecular
More InformationProfessor Joaquim Ferreira is a Professor of Neurology and Clinical Pharmacology at the Faculty of Medicine, University of Lisbon and Head of the Laboratory of Clinical Pharmacology and Therapeutics. He completed his medical degree and PhD in Neurology at the University of Lisbon. He became interested in movement disorders during his medical degree and later undertook a Clinical Pharmacology fellowship with Prof Olivier Rascol in Toulouse, France. He is currently the chair of the European Section of The International Parkinson and Movement Disorder Society. His major research interests are neuropharmacology, Parkinson’s disease, dystonia and Huntington’s disease.
|
|
Gian Luca Forni - Ospedia Galliera
More InformationDr Gian Luca Forni is a hematologist with an expertise in iron chelation therapies indicated for systemic siderosis. He has experience with the safety profile of deferiprone and notably for the neutropenia and agranulocytosis. He collaborated on the first pilot trial of chelation with deferiprone in “Neurodegeneration with Brain Iron Accumulation”.
|
|
Holm Graessner - Eberhard Karls Universitaet Tuebingen
More InformationHolm Graessner, PhD, MBA, is managing director of the Rare Disease Centre Tübingen and head of the research management unit of the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. He has profound experience in project management of collaborative projects such as the FP6 and FP7 EU projects EUROSCA, MEFOPA, RATstream, SENSE-PARK, TreatPolyQ, MultISyn and NeurOmics.
|
|
Werner Poewe - Medizinische Universitat Innsbruck
More InformationProfessor Werner Poewe is Professor of Neurology and Director of the Department of Neurology at Medical University Innsbruck, Austria. Professor Poewe’s main research interests are in the field of Parkinson’s Disease and Movement Disorders where he has authored and co-authored more than 550 original articles and reviews. Prof. Poewe served as President of the International Movement Disorder Society from 2000 through 2002 and as chair of the MDS European Section from 2011-2013 and as President of the Austrian Society of Neurology from 2002 to 2004 as well as President of the Austrian Parkinson’s Disease Society from 1996-2009. Werner Poewe is Corresponding Member of the American Neurological Assocation and the French Neurological Society and Honorary Member of the German Neurological Society as well as the Japanese Neurological Society . In 1995 he received the Walther-Birkmayer-Prize of the Austrian PD Society and in 2006 the Dingebauer Prize of the German Neurological Society.
|
|
Olivier Rascol - Inserm F-CRIN
More InformationProfessor Olivier Rascol, MD, PhD, neurologist, professor of neurology at the Toulouse University. Head of the Toulouse Clinical Investigation Center (CIC 1436), coordinator of the NS PARK/FCRIN Network, coordinator of the French Clinical Research Infrastructure Network FCRIN.
|
|
Evžen Růžička - Univerzita Karlova v Praze
More InformationEvžen Růžička is a Professor and Chairman in the Department of Neurology, Charles University, Prague, Czech Republic. He obtained his neurological training at the university departments of neurology in Prague and at La Salpetriere, Paris, France. He has edited or co-edited several books including the Gait Disorders volume of Advances in Neurology, and has published original articles covering Parkinson’s disease and other movement disorders. In 2015, Dr. Růžička was elected Chair-Elect of the European Section of the Movement Disorders Society.
|
|
Delphine Smagghe - INSERM - Transfert SA
More InformationDelphine joined Inserm Transfert in 2006 and leads the neurosciences group within the Collaborative Research Funding / European Affairs department. She holds a Master degree in chemical formulation and a post-Master degree in management of technological innovation in the bio-industries. Delphine has a strong track record of project management and proposal writing over the last 11 years. She also leads a process in the frame of the ISO 9001-2008 certification of the department, for the management of European and International biomedical research projects.
|
|
Eduardo Tolosa - Fundació privada Clínic per a la Recerca Biomèdica
More InformationProf. Tolosa is a neurologist by the American Board of Neurology and Psychiatry. He is a fellow of the American Academy of Neurology, the American Neurological Association and the Royal College of Physicians, and a founding member of the Movement Disorder Society (MDS). He’s currently a Senior Consultant at the Department of Neurology at the Hospital Clinic Universitari in Barcelona
Prof. Tolosa’s research interests have centered on movement disorders and particularly in issues related to experimental therapeutics, etiology and pathophysiology of various parkinsonisms. His team has been among the first in Europe to evaluate efficacy of novel surgical strategies for Parkinson’s disease such as subthalamic nucleus stimulation and its impact upon patients cognition and quality of life. In addition, during the last years, he has dedicated his investigations to the study of the asymptomatic individuals carrying PD-causative mutations in the LRRK2 gene.
|
|
JC Corvol - Inserm
More InformationJean-Christophe Corvol is Professor of Neurology at the Pitié-Salpêtrière, head of the Clinical Research Center for Neurosciences at the Institute of Brain and Spinal cord (ICM), co-Chair of the French clinical research network for Parkinson’s disease and Movement disorders (NS-Park). His field of interest is pharmacogenetics and gene modifiers in Parkinson’s disease.
|
|
Pauline Guyon - CHRUL
More InformationPauline Guyon is a project manager for Fair Park II. In this position, she is in charge of running the project in close collaboration with the coordinator (Prof David Devos) and oversees its implementation. She also provides advice and support to the members of the project and she leads the consortium with the assistance of colleagues at Inserm-Transfert. She previously worked for five years as legal counsel for the research activities of Lille University Hospital. During this period she gained clinical trial expertise in terms of writing and editing trial protocols through to the completion of clinical trials.
|
|
Bart Post - RUNMC
More InformationBart Post was born on March 30, 1972 in Grootebroek, the Netherlands. He obtained his medical degree in 1999 at the University of Maastricht (with honors). In 2000 he started his training as a resident in Neurology at the Academic Medical Centre in Amsterdam (head: prof. dr. M. Vermeulen), which he completed in December 2008. In 2002 he started a research project on ‘Prognosis in Parkinson’s disease’ that resulted in a PhD thesis in 2009. In 2006 he started a master of Sciences (MSc) education in clinical epidemiology at the EMGO institute in Amsterdam. In 2009 he was certified as a clinical epidemiologist. Since 2010 he works as a movement disorder neurologist in the Parkinson Centre in the Radboudumc in Nijmegen (head: prof. dr. B. Bloem). He is part of the steering committee of two large Parkinson trials in the Netherlands: the LEAP-trial (Early administration of levodopa in de novo PD); and the CHEVAL-trial (administration of acetylcholine inhibitors in PD patients with hallucinations). Furthermore he was an expert-rater at the EARLY-STIM trial (German-French trial on DBS early in the course of PD). At the department of neurology of the Radboudumc he is chair of the residency program for neurologists.
|